Arginine methyltransferase inhibitors and uses thereof
View Patent ↗Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
X is N, Z is NR 4 , and Y is CR 5 ; or
X is NR 4 , Z is N, and Y is CR 5 ; or
X is CR 5 , Z is NR 4 , and Y is N; or
X is CR 5 , Z is N, and Y is NR 4 ;
R X is optionally substituted C 1-4 alkyl or optionally substituted C 3-4 cycloalkyl;
L 1 is a bond, —O—, —N(R B )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R B )—, —C(O)N(R B )N(R B )—, —OC(O)—, —OC(O)N(R B )—, —NR B C(O)—, —NR B C(O)N(R B )—, —NR B C(O)N(R B )N(R B )—, —NR B C(O)O—, —SC(O)—, —C(═NR B )—, —C(═NNR B )—, —C(═NOR A )—, —C(═NR B )N(R B )—, —NR B C(═NR B )—, —C(S)—, —C(S)N(R B )—, —NR B C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R B )SO 2 —, —SO 2 N(R B )—, or an optionally substituted C 1-6 saturated or unsaturated hydrocarbon chain, wherein one or more methylene units of the hydrocarbon chain is optionally and independently replaced with —O—, —N(R B )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R B )—, —C(O)N(R B )N(R B )—, —OC(O)—, —OC(O)N(R B )—, —NR B C(O)—, —NR B C(O)N(R B )—, —NR B C(O)N(R B )N(R B )—, —NR B C(O)O—, —SC(O)—, —C(═NR B )—, —C(═NNR B )—, —C(═NOR A )—, —C(═NR B )N(R B )—, —NR B C(═NR B )—, —C(S)—, —C(S)N(R B )—, —NR B C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R B )SO 2 —, or —SO 2 N(R B )—;
each R A is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom;
each R B is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group, or an R B and R W on the same nitrogen atom may be taken together with the intervening nitrogen to form an optionally substituted heterocyclic ring;
R W is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; provided that when L 1 is a bond, R W is not optionally substituted aryl or optionally substituted heteroaryl;
R 3 is hydrogen, C 1-4 alkyl, or C 3-4 cycloalkyl;
R 4 is hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-7 cycloalkyl, optionally substituted 4- to 7-membered heterocyclyl; or optionally substituted C 1-4 alkyl-Cy;
Cy is optionally substituted C 3-7 cycloalkyl, optionally substituted 4- to 7-membered heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
R 5 is hydrogen, halo, —CN, optionally substituted C 1-4 alkyl, or optionally substituted C 3-4 cycloalkyl.
2. The compound of claim 1 , wherein the compound is of Formula (II) or (III):
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is of Formula (IV) or (V):
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein L 1 is a bond and R W is optionally substituted carbocyclyl.
5. The compound of claim 4 , wherein L 1 is a bond and R W is optionally substituted cyclohexyl.
6. The compound of claim 1 , wherein L 1 is a bond and R W is optionally substituted heterocyclyl.
7. The compound of claim 6 , wherein L 1 is a bond and R W is optionally substituted piperidine.
8. The compound of claim 1 , wherein R 3 is C 1-4 alkyl.
9. The compound of claim 8 , wherein R 3 is methyl.
10. The compound of claim 1 , wherein R 3 is hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, or cyclobutyl.
11. The compound of claim 1 , wherein R 4 is hydrogen.
12. The compound of claim 1 , wherein R 4 is optionally substituted C 1-6 alkyl.
13. The compound of claim 12 , wherein R 4 is unsubstituted C 1-6 alkyl.
14. The compound of claim 13 , wherein R 4 is methyl.
15. The compound of claim 1 , wherein R 5 is hydrogen.
16. The compound of claim 1 , wherein R 5 is optionally substituted C 1-4 alkyl.
17. The compound of claim 16 , wherein R 5 is unsubstituted C 1-4 alkyl.
18. The compound of claim 17 , wherein R 5 is methyl.
19. The compound of claim 1 , wherein R X is optionally substituted C 1-4 alkyl.
20. The compound of claim 19 , wherein R X is unsubstituted C 1-4 alkyl.
21. The compound of claim 20 , wherein R X is methyl.
22. The compound of claim 19 , wherein R X is ethyl, isopropyl, propyl, butyl, hydroxyethyl, methoxyethyl, cyclopropyl, or cyclobutyl.
23. The compound of claim 1 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
24. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
25. A kit or packaged pharmaceutical comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and instructions for use thereof.
26. A method of inhibiting an arginine methyl tranferase (RMT) comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
27. The method of claim 26 , wherein the arginine methyl transferase is PRMT1, PRMT3, PRMT6, PRMT8, or CARM1.
28. The method of claim 27 , wherein the arginine methyl transferase is PRMT1.
29. A method of modulating gene expression comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
30. A method of modulating transcription comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
31. A method for therapeutically treating a RMT-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
32. The method of claims 31 , wherein the RMT-mediated disorder is a PRMT1-mediated disorder, a PRMT3-mediated disorder, a PRMT6-mediated disorder, a PRMT8-mediated disorder, or a CARM1-mediated disorder.
33. The method of claim 32 , wherein the RMT-mediated disorder is a PRMT1-mediated disorder.
34. The method of claim 31 , wherein the disorder is a proliferative disorder, a neurological disorder, a muscular dystrophy, an autoimmune disorder, a vascular disorder, or a metabolic disorder.
35. The method of claim 34 , wherein the proliferative disorder is cancer.
36. The method of claim 34 , wherein the neurological disorder is amyotrophic lateral sclerosis.